Expert Review of Neurotherapeutics

Expert Review of Neurotherapeutics is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neurological disorders and treatments, Epilepsy research and treatment and Parkinson's Disease Mechanisms and Treatments, together about 21% of its articles. Its main subfields are Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)

Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Review of Neurotherapeutics, part of the Expert Collection brand. Expert Review of Neurotherapeutics [ISSN 1473-7175]; [e-ISSN 1744-8360] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on the use of drugs and medicines in clinical neurology and neuropsychiatry. Articles focus on the following key areas: Disease management New medicines and drugs in neurology Therapeutic indications, diagnostics, medical treatment guidelines Neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's Please note that the journal does not publish case reports or case series. Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Review of Neurotherapeutics, part of the Expert Collection brand. For any pre-submission enquiries, please contact the Commissioning Editor.

From the journal's Aims & Scope

Research area (LetPub): CLINICAL NEUROLOGY-PHARMACOLOGY & PHARMACY

Editor-in-chief René Ernst NielsenPublisher website

Editorial board by country: none in mainland China; most named United States 11, Italy 6, United Kingdom 4, Australia 2, Brazil 2 (31 members with a country) Editorial board ↗Publisher website · 2026-10-01

CAS Journal Ranking

JCR / CiteScore quartiles on the journal's website

• JCR Q1 · best quartile · 2025
• CiteScore Q1 · 2025

Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

MEDLINEEmbaseCASCurrent ContentsPublisher website

Other: Index Medicus, Biobase, Index to Scientific Reviews®, Journal Citation Reports/Science Edition, PsychINFO

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

4.35LetPub · 2026-09-13

Impact factor (publisher) 2025

4.3Publisher website · 2026-10-01

5-year impact factor (publisher) 2025

4.3Publisher website · 2026-10-01

CiteScore 2026-06

6.3LetPub · 2026-09-13

CiteScore (publisher) 2025

6.3Publisher website · 2026-10-01

SJR 2026-06

1.11LetPub · 2026-09-13

SJR (publisher) 2025

1.11Publisher website · 2026-10-01

SNIP 2026-06

1.28LetPub · 2026-09-13

SNIP (publisher) 2025

1.28Publisher website · 2026-10-01

h-index

63LetPub · 2026-09-13

h-index

125OpenAlex · 2026-10-01

i10-index

2,078OpenAlex · 2026-10-01

2-year mean citedness

4.3OpenAlex · 2026-10-01

Self-citation rate

2.3%LetPub · 2026-09-13

Share of gold OA articles

7.36%LetPub · 2026-09-13

Volume

Articles per year

94LetPub · 2026-09-13

Downloads per year (publisher)

610,000Publisher website · 2026-10-01

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

4–8 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly easyLetPub · 2026-09-13

Acceptance rate (publisher)

22%Publisher website · 2026-10-01

Submission to first decision

1 daysPublisher website · 2026-10-01

First decision after review

40 daysPublisher website · 2026-10-01

Acceptance to publication

8 daysPublisher website · 2026-10-01

Peer review

Double anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Taylor and Francis Ltd.

Country or region

ENGLAND

Language

English

ISSN

1473-7175

Electronic ISSN

1744-8360

Latest issue on the website

Volume 26, Issue 9 (2026)

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website